Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS Analysis.

CONCLUSION: Adjusted analyses leveraging IPD demonstrates that guselkumab has a significantly higher probability of achieving and maintaining PASI treatment response through week 40 compared with ustekinumab.
PMID: 31652347 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - October 24, 2019 Category: Dermatology Authors: Diels J, Thilakarathne P, Cameron C, McElligott S, Schubert A, Puig L Tags: Br J Dermatol Source Type: research